Hudson Bay Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Hudson Bay Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.27M	Sell	364,740 -257,760	-41%	-$3.69M	0.02%	489
2025 Q4	$8.86M	Sell	622,500 -1,452,500	-70%	-$14.3M	0.03%	368
2025 Q3	$16.4M	Sell	2,075,000 -137,690	-6%	-$980K	0.05%	259
2025 Q2	$12.7M	Sell	2,212,690 -257,720	-10%	-$1.66M	0.04%	305
2025 Q1	$20.2M	Buy	2,470,410 +665,610	+37%	+$6.16M	0.06%	261
2024 Q4	$17M	Buy	1,804,800 +379,800	+27%	+$3.95M	0.06%	265
2024 Q3	$15.2M	Buy	1,425,000 +357,500	+33%	+$3.89M	0.06%	201
2024 Q2	$10.6M	Buy	1,067,500 +265,000	+33%	+$2.72M	0.05%	223
2024 Q1	$9.45M	Buy	802,500 +442,500	+123%	+$5.66M	0.05%	180
2023 Q4	$5.11M	Buy	360,000 +185,000	+106%	+$2.1M	0.03%	296
2023 Q3	$2.13M	Buy	175,000 +20,000	+13%	+$258K	0.02%	468
2023 Q2	$1.95M	Buy	155,000 +30,000	+24%	+$356K	0.01%	507
2023 Q1	$1.39M	Hold	125,000	–	–	0.01%	566
2022 Q4	$1.53M	Hold	125,000	–	–	0.02%	648
2022 Q3	$1.3M	Sell	125,000 -55,000	-31%	-$613K	0.01%	816
2022 Q2	$1.93M	Buy	180,000 +131,204	+269%	+$1.08M	0.01%	811
2022 Q1	$462K	Buy	+48,796	New	+$458K	0.01%	883
2021 Q4	–	Sell	-250,000	Closed	-$2.39M	–	1127
2021 Q3	$2.39M	Sell	250,000 -65,000	-21%	-$665K	0.03%	589
2021 Q2	$3.04M	Buy	+315,000	New	+$3.07M	0.04%	501
2020 Q3	–	Sell	-39,900	Closed	-$601K	–	581
2020 Q2	$601K	Sell	39,900 -65,100	-62%	-$793K	0.01%	401
2020 Q1	$970K	Sell	105,000 -45,000	-30%	-$428K	0.02%	333
2019 Q4	$1.46M	Buy	150,000 +38,400	+34%	+$352K	0.03%	307
2019 Q3	$895K	Buy	111,600 +71,600	+179%	+$777K	0.02%	325
2019 Q2	$499K	Hold	40,000	–	–	0.01%	351
2019 Q1	$544K	Sell	40,000 -110,000	-73%	-$1.34M	0.01%	604
2018 Q4	$1.44M	Buy	150,000 +10,000	+7%	+$110K	0.02%	576
2018 Q3	$1.69M	Buy	140,000 +40,000	+40%	+$559K	0.02%	495
2018 Q2	$1.56M	Sell	100,000 -100,000	-50%	-$1.51M	0.02%	563
2018 Q1	$3.01M	Buy	200,000 +100,000	+100%	+$1.52M	0.06%	342
2017 Q4	$1.44M	Hold	100,000	–	–	0.03%	364
2017 Q3	$1.51M	Sell	100,000 -100,000	-50%	-$1.32M	0.04%	268
2017 Q2	$2.01M	Sell	200,000 -100,000	-33%	-$805K	0.04%	335
2017 Q1	$2.14M	Buy	+300,000	New	+$1.9M	0.03%	455

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Hudson Bay Capital Management's FOLD Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Amicus Therapeutics (FOLD) stake by 41% in Q1 2026, selling an estimated $3.69M and leaving 364,740 shares worth $5.27M. The position accounts for 0.02% of the portfolio, ranked #489.

Hudson Bay Capital Management first reported a position in FOLD in Q1 2017 and has held it in 33 quarters since. The position peaked at $20.2M in Q1 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Hudson Bay Capital Management held 364,740 shares of Amicus Therapeutics worth $5.27M as of Q1 2026.
Hudson Bay Capital Management sold 257,760 Amicus Therapeutics shares in Q1 2026, an estimated $3.69M.
Amicus Therapeutics made up 0.02% of Hudson Bay Capital Management's portfolio in Q1 2026, its #489 holding.
Hudson Bay Capital Management first reported a position in Amicus Therapeutics in Q1 2017 and has held it in 33 quarters since.
Hudson Bay Capital Management's Amicus Therapeutics position peaked at $20.2M in Q1 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.